Genocea Biosciences Stock News

Genocea Biosciences (NASDAQ:GNCA) is scheduled to announce Q4 results on Thursday, Mar. 10, before market open.Consensus EPS estimate is -$0.18 and consensus revenue estimate is $0.05M.

Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors

Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors

CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth qua

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quart

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 th at 10:40 A.M. ET.

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Ch

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior l

Genocea Biosciences Inc (GNCA) shares closed today 19.7% higher than it did at the end of yesterday. The stock is currently down 48.6% year-to-date, down 51.7% over the past 12 months, and down 96.7% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.35 and as low as $0.91 this week.Shares closed 69.3% below its 52-week high and 36.8% above its 52-week low.Trading volume this week was 84.2% lower than the 10-day average and 56.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -351.5% The company's stock price performance over the past 12 months lags the peer average by -520.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Genocea Biosciences Inc (GNCA) shares closed today 19.7% higher than it did at the end of yesterday. The stock is currently down 57.0% year-to-date, down 58.9% over the past 12 months, and down 97.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.35 and as low as $0.91 this week.Shares closed 69.3% below its 52-week high and 36.8% above its 52-week low.Trading volume this week was 55.2% higher than the 10-day average and 69.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -379.0% The company's stock price performance over the past 12 months lags the peer average by -454.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENSC, TKC, GNCA, IINN, and BFRI. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.